Raptiva side effects lead to serious
Health Risks
On April 8, 2009, the FDA announced a Raptiva
recall.
Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab),
announced that it has begun a voluntary, phased withdrawal of the
product from the U.S. market. The company is taking this action
because of a potential risk to patients of developing progressive
multifocal leukoencephalopathy (PML), a rare, serious, progressive
neurologic disease caused by a virus that affects the central nervous
system.
The law firm of Morelli Ratner PC is reviewing potential
claims for individuals who have suffered serious injury or death
as a result of taking Raptiva. The psoriasis drug has been linked
to causing severe and sometimes fatal neurologic diseases. The potential
for a Raptiva lawsuit is being reviewed and evaluated on behalf
of individuals who have been diagnosed with:
- Invasive Fungal Disease
- Progressive multifocal leukoencephalopathy (PML)
- Viral Meningitis
- Sepsis
- Brain Infection (unknown type)
- Other injuries or infections
If you or a loved one has developed a severe medical
condition or died while taking Raptiva contact Morelli Ratner immediately
for help. Our firm is representing people who have been injured
by Raptiva use. Morelli Ratner has extensive experience in defective
drug litigation and will fight to protect your rights.
Submit
your Free Raptiva Case Evaluation Form
Potential Raptiva cases are being reviewed
throughout the United States. There are no fees or expenses unless
a recovery is obtained.
What is Raptiva?
Raptiva is a medication given by injection to patients
with moderate to severe plaque psoriasis, the most common case of
psoriasis. Raptiva was approved for adults with moderate to severe
plaque psoriasis who are candidates for systemic (whole body) therapy
or phototherapy. The drug works by suppressing T-cells (blood cells
that help fight infection) in the immune system. These cells, when
activated, migrate to the skin and cause inflammation which results
in the red, inflamed and scaly patches of skin, which is associated
with psoriasis. By suppressing T-cells, Raptiva decreases the function
of the immune system which increases a patient's susceptibility
to infections.
If you are concerned about your use of Raptiva, contact Raptiva
lawyers at Morelli Ratner. Their knowledgeable attorneys are prepared
to assist you..
Submit
your Free Raptiva Case Evaluation Form
Raptiva Lawsuit
On February 19th, 2009, the FDA issued a public
health advisory about a rare brain infection among some users of
Raptiva. The FDA reports that there have been a number of cases
of progressive multifocal leukoencephalopathy (PML) in people taking
Raptiva. Some Raptiva users have died. In October 2008, a Black
Boxed Warning was added to the Raptiva label warning of the risks
of life-threatening infections, including PML.
Submit
your Free Raptiva Case Evaluation Form |
